Truist Financial analyst David S Macdonald has maintained their bullish stance on CI stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David S Macdonald has given his Buy rating due to a combination of factors including Cigna’s strategic investment in Shields Health Solutions, which is expected to enhance its specialty pharmacy capabilities. Shields Health Solutions has a strong customer base and impressive revenue growth, which aligns well with Cigna’s goals of capturing additional healthcare spending and achieving long-term income growth targets.
Moreover, Cigna’s broad capabilities in the specialty market and its history of successful acquisitions position it favorably to benefit from market tailwinds and barriers to entry. The company’s capital-efficient model and strong free cash flow generation are anticipated to support continued growth. Additionally, management’s reaffirmation of the FY25 adjusted EPS guidance underscores confidence in the company’s financial trajectory, further justifying the Buy rating.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $334.00 price target.